Gemcitabine through an artery versus by vein after radiation
Treatments studied
Part of Cancer clinical trials.
This study tests whether giving gemcitabine directly into the artery feeding the pancreas (instead of through an IV) works better after you finish radiation therapy. It may help patients by improving how the medicine reaches the tumor while comparing side effects and outcomes between the two delivery methods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic adenocarcinoma confirmed by a pathology or cytology test, and it was diagnosed recently (timing depends on which treatment cycle you join).
- Your pancreatic cancer is locally advanced and not removable by surgery, confirmed by a CT or MRI close to starting radiation/chemotherapy planning.
- You must be an adult (18+) and able to do daily activities fairly well (ECOG performance status 0 or 1).
- Your blood counts and organ/liver/kidney labs must be high enough before starting treatment, including neutrophils, platelets, hemoglobin, kidney function, and liver/bilirubin levels.
- You must have planned radiation treatment that allows SBRT safely, and an expert team must confirm there’s a safe artery path to deliver the drug through a catheter; also no spread to other organs.
- You must be willing and medically able to start the randomized treatment on the required schedule after imaging, have baseline tumor scans, and be available for at least 8 months if assigned to the catheter arm or the standard IV arm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how safe and effective nab-paclitaxel plus gemcitabine chemo is when paired with proton radiation for locally advanced pancreatic cancer that cannot be removed with surgery. It may help shrink the tumor and improve local control.
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
This trial tests whether giving two already-approved chemotherapy drugs and radiation before surgery works better for localized pancreatic cancer. It’s meant for people whose cancer looks removable by surgery and who haven’t had prior pancreatic cancer treatment.
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
This trial tests a treatment called transcatheter arterial infusion, where chemotherapy drugs are delivered directly to the tumor through a thin tube in an artery. It's for people with advanced pancreatic cancer who haven't had other treatments yet.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.